Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Chronic Renal Failure

Free Subscription Articles published in Nat Med Retrieve available abstracts of 10 articles: HTML format

Single Articles

May 2025
1. SUN Z, Yi Z, Wei C, Wang W, et al
   LILRB3 genetic variation is associated with kidney transplant failure in African American recipients.
   Nat Med. 2025;31:1677-1687.
   PubMed     Abstract available
   
   
   January 2025
2. TEERAWATTANANON Y, Chavarina KK, Phannajit J, Sutawong J, et al
   The Access to Dialysis in Low- and Middle-Income Countries Commission: lessons for universal health coverage.
   Nat Med. 2025;31:19-21.
   PubMed    
   
   
   October 2024
3. VADUGANATHAN M, Filippatos G, Claggett BL, Desai AS, et al
   Author Correction: Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes.
   Nat Med. 2024 Oct 28. doi: 10.1038/s41591-024-03372.
   PubMed    
   
   
   
4. APPERLOO EM, Gorriz JL, Soler MJ, Cigarran Guldris S, et al
   Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial.
   Nat Med. 2024 Oct 25. doi: 10.1038/s41591-024-03327.
   PubMed     Abstract available
   
   
   September 2024
5. HOBBS FDR, McManus RJ, Taylor CJ, Jones NR, et al
   Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial.
   Nat Med. 2024 Sep 30. doi: 10.1038/s41591-024-03263.
   PubMed     Abstract available
   
   
   
6. VADUGANATHAN M, Filippatos G, Claggett BL, Desai AS, et al
   Finerenone in Heart Failure and Chronic Kidney Disease with Type 2 Diabetes: the FINE-HEART pooled analysis of cardiovascular, kidney, and mortality outcomes.
   Nat Med. 2024 Sep 1. doi: 10.1038/s41591-024-03264.
   PubMed     Abstract available
   
   
   July 2024
7. CHERTOW GM, Chang AM, Felker GM, Heise M, et al
   Author Correction: IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial.
   Nat Med. 2024 Jul 3. doi: 10.1038/s41591-024-03156.
   PubMed    
   
   
   June 2024
8. MANN JFE, Rossing P, Bakris G, Belmar N, et al
   Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial.
   Nat Med. 2024 Jun 24. doi: 10.1038/s41591-024-03133.
   PubMed     Abstract available
   
   
   May 2024
9. CHERTOW GM, Chang AM, Felker GM, Heise M, et al
   IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial.
   Nat Med. 2024 May 25. doi: 10.1038/s41591-024-03043.
   PubMed     Abstract available
   
   
   
10. KONDO T, Jhund PS, Gasparyan SB, Yang M, et al
    A hierarchical kidney outcome using win statistics in patients with heart failure from the DAPA-HF and DELIVER trials.
    Nat Med. 2024;30:1432-1439.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Chronic Renal Failure is free of charge.